ClinicalTrialsFinder
RecruitingNCT07132567

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Sponsor

Kyowa Kirin Co., Ltd.

Enrollment

15 participants

Start Date

May 2, 2025

Study Type

OBSERVATIONAL

Conditions

Mycosis FungoidesSezary Syndrome

Summary

The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.

Eligibility

Min Age: 19 Years

Inclusion Criteria3

  • Adults 19 years of age or older
  • Individuals who are confirmed to have received administration of the study drug for the purpose of "the treatment for adult patients with fungoidal granuloma or Sezary syndrome who have received one or more systemic therapies," or who are considered to require administration of the study drug in the investigator's opinion
  • Individuals who (or whose legally acceptable representatives) signed the Consent to Use of Personal Information of their own free will for participation in this use-result surveillance

Exclusion Criteria3

  • Patients with hypersensitivity to any ingredients of this drug
  • Patients who intend to use this drug for non-approved indications
  • Patients who participated in a pre-market clinical trial of the study drug and received administration of the study drug

Interventions

DRUGPoteligeo 20mg

Poteligeo 20mg

Locations(6)

Kosin University Gospel Hospital

Busan, Busan Metropolitan City, South Korea

Chung-Ang University Hospital

Seoul, South Korea

Ewha Womans University Mokdong Hospital

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07132567

Related Trials

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

NCT065084632 locations

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

NCT070554771 location

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

NCT062078121 location

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

NCT053577941 location

Extracorporeal Photopheresis in Sezary Syndrome

NCT051575813 locations